A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas

Trial Profile

A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Durvalumab (Primary) ; Ibrutinib (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 10 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 12 May 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 23 Mar 2015 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top